



EXPRESS MAIL NO. EV170132350US

RESPONSE UNDER 37 C.F.R. § 1.116
EXPEDITED PROCEDURE - EXAMINING GROUP 1600

TECHNICAL CENTER 600/2900

SEP 10 2002

RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Tongtong Wang et al.
Application No. : 09/651,563
Filed : August 29, 2000
For : COMPOSITIONS AND METHODS FOR THE THERAPY
AND DIAGNOSIS OF LUNG CANCER

Examiner : Michael L. Borin, Ph.D.
Art Unit : 1631
Docket No. : 210121.478C10
Date : September 10, 2002

Box AF
Commissioner for Patents
Washington, DC 20231

RESPONSE UNDER 37 C.F.R. § 1.116

Commissioner for Patents:

In response to the Office Action dated July 19, 2002, please amend the application
as follows:

In the Claims:

Please cancel claims 1-3, 11-60, and 63-65.

Please amend claims 62, 66, and 67 to read as follows:

62. (Amended) An isolated polynucleotide comprising a sequence having at
least 90% identity with the entirety of the sequence of SEQ ID NO:808, wherein the
polynucleotide can be used in the detection of lung cancer.

OK do end
m.b. 09/27/02